Kwasa Alzheimerbe dǝ shima kwasa donyi kǝrǝn kamma wuzǝyin ma, shi donyi kǝrǝn lan cells so dǝga wuzayin ma kuru suwudin, adǝye sǝkǝ kǝrǝn dǝga wuzǝyin ma, tafakkar so, hangal so.
Awo shima dǝ shima kambowo so sha sǝkǝ dementia dǝga suwudin, 60-80% zaso samma so.
Kwasa shima adǝ dareramnzǝ lan kam cejin, tǝmatǝnyi lan shi donyi saa 4-8 ro notǝnama, amma la dǝ saa 20 maro notǝyin.
Adadu donyi kwasa Alzheimerbe suwudin dǝ nǝm gade gade lan kara, adadu donyi kǝra tǝdin dǝ gade gade lan kara.
Alzheimer's Associationye gultǝnzǝ lan, kwasa Alzheimerbe dǝ shima sawu am batǝ ye kǝn arakkǝmi wo suro lardǝ United Statesbe lan, kuru shima sawu am batǝ ye kǝn uwumi wo am saa 65 lan kozǝna dǝn.
Saa 2019 lan, kwasa Alzheimer ye shima dalil ba do am 121,944 ye United States lan nu'aduna ma wo.
Notә tawadәro faidaa mbeji kәrmu donyi Alzheimerbe suwudin ma dә shi tilonzә gәnyi, amma kazәyiya so kuru kazәyiya nәlewabe gade soye suwudin ma dalil kwasa shima dәben.
Kwasa dǝ fuwujinna son, kam so dǝ cidawa kǝnǝngabe jili kǝmbu bowota, kǝlanza tulta, kazumu yikko, adǝ ye zǝkcin, kwasa donyi kǝmbu be suwudin ma, kwasa wa donyi kǝntǝwuna awu kazǝyiya gade so.
Kǝlâ adu ye, kam donyi Alzheimer diseasebe mbeji ma dǝ shima tajirwa donyi fǝrǝssǝbe, pneumoniabe, a kasuwawa gade soye.
Zhu B, Chen X, Li W, Zhou D: Effect of Alzheimer Disease on Prognosis of Intensive Care Unit (ICU) Patients: A Propensity Score Matching Analysis. Med Sci Monit. 2022, 28 (): e935397.
Almeida MC, Gomes Cde M, Nascimento LF: Spatial distribution of deaths due to Alzheimer's disease in the state of São Paulo, Brazil. Sao Paulo Med J. 2014, 132 (4): 199-204.
Aevarsson O, Svanborg A, Skoog I: Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Arch Neurol. 1998, 55 (9): 1226-32.
Breitner JC: Clinical genetics and genetic counseling in Alzheimer disease. Ann Intern Med. 1991, 115 (8): 601-6.
Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, Rasmussen SA, Roqué Figuls M, Alcolea D, Videla L, Barroeta I, Benejam B, Altuna M, Padilla C, Pegueroles J, Fernandez S, Belbin O, Carmona-Iragui M, Blesa R, Lleó A, Bejanin A, Fortea J: Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Netw Open. 2022, 5 (5): e2212910.
['Kәlanzәma ro cistәgә: liita']
['Websayit adә ilmu matәbe-a bayan matәbe bas nankaro cedo kuru shawari liyitabe au cidawa cidawu liyitabe diobe gәnyi.']
['Bayanwa yitagattәgәna so dә kwasa laa au kwasa laa asutu au kurun dio ro faidatәmba, kuru am doni shawaria liyitaye mazayin so dә dokta lasisatәna ro manatә saadin.']
['Martәne netәram kәrәnbe do korowa dә ro jawawu suwudin dә, taganasmaro kalkal gәnyi sa lamba isәna dәn. Misallo, nәm nguwu am doni kwasa laa taganasbe shiro asuzana ma.']
["Sambi so ro shawari kam litari nәm au kam gade nasha nәlewabe nozәna ma ye la'atar ro matәne. Shawari kam litaribe nozәna ma ro tәmmaro hangal gәnyi gәnane au sha matә lan loktu gozәnyi awo laa website adәn kәrәnәmma yen. Nyiye kurun nәlewabe batәrammin maa, talfon 911 lan buwoze au njim liwalabe karungu ma ro lenәme. Alaka nәlewa-a dondibe ba ma tuwandin web site adә men au shilan faidatәmen. BioMedLib-a cidawunzә-a, au kam do web site adә ro banazәyin-aye, affima bayanzәna au manazәna ma sadimba, bayanwa suro adәben tuwandin au shilan faidatәmen."]
['Suro nәm kәla nәm ngәla yen awo laa au kare laa kәla intanetndeyen au cidawandeyen mbejiye hakku nәm kakkadi ruotәbe nyiro kalzәna ma ye mbeji maa, nyi (au wakkilnәm) andero watiya zuwune awo au kare dә tutuluwu, au na dәro nazәgә dә tutuluwu.']
["Zande so dә ruwo lan zuzaiya, email men (adәretәm emailye dә nasha 'Lam'atarro manәmin)"]
['DMCA ye məradənzə bayan kəla nzətkawo kərmaabedəbe bayanwa anyi surodən mbejiro: (1) bayan kəla cida nzətkawobe dunonzə dunonzə kaltəgəbe dunonzə kaltəgəbe; (2) bayan kəla awoa zortəbe dunonzə kaltəgəbe dunonzə kuru bayan kəzəkə andeya səkə awoadəga fandəmin; (3) bayan kəlanəm lamba fantəbe, suro nzəranəm-a, lamba telehonbe-a kuru email-be-a; (4) bayan kəlanəmbe kəla nyiye tawatkənənde kəla awoa zortəbe dunonzə kaltəgəbe dunonzəye dunonzəye səkə au wakilinzəye, au shara laabe səkə; ']
['(5) bayan nyima, kalima jirebero, ruwotәgәna, bayan suro watiyade dә kalkalzәna kuru nyiye hakku kәlanzәbe hakkuwa ləbtәma soye warmatәgәbe dәga nonәmma;']
['kuru (6) mukko dunowa au lantarkibe hakkiwa ləbtamabe au kam laaye wakil zəben cida sədənabe. ']
['Bayanna samibe samma kәltәgә nyiye mowonzә zәktә lamar buruwunәmye gәrәmin.']
['Lǝtǝram']
['Martәne ande ro watiya emailye lan koro/shawari laa manane.']
How deadly is alzheimer?
Alzheimer's disease is a progressive neurological disorder that causes brain cells to degenerate and die, leading to a decline in memory, thinking, and reasoning skills.
It is the most common cause of dementia, accounting for 60-80% of all cases.
The disease is ultimately fatal, with the average life expectancy after diagnosis being 4-8 years, although some people can live up to 20 years with the disease.
The mortality rate for Alzheimer's disease varies depending on the study and the population being examined.
According to the Alzheimer's Association, Alzheimer's disease is the sixth leading cause of death in the United States, and it is the fifth leading cause of death for those aged 65 and older.
In 2019, Alzheimer's disease was reported as the underlying cause of death for 121,9444 people in the United States.
It is important to note that the mortality rate for Alzheimer's disease is not solely due to the disease itself, but also due to complications and other health issues that arise as a result of the disease.
As the disease progresses, individuals may experience difficulty with activities of daily living, such as eating, bathing, and dressing, which can lead to malnutrition, infections, and other health problems.
Additionally, individuals with Alzheimer's disease may be at an increased risk of falls, pneumonia, and other infections.
While there is currently no cure for Alzheimer's disease, there are treatments available that can help manage symptoms and improve quality of life.
Research is ongoing to develop new treatments and ultimately find a cure for this devastating disease.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
